In addition to SGLT2 inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and Glucagon-Like Peptide-1 (GLP-1) receptor agonists have shown significant efficacy for T2D management. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.